Ozone Pharmaceuticals, a division of Ozone Group of Companies based in Delhi, has recently received a patent for the molecule of diabetic retinopathy which will have its therapeutic effect in chronic venous insufficiency, diabetic retinopathy, glaucoma and other micro-blood vessel disorders.
“This is one-of-its kind patent received by any company till date. Ozone has done a clinical research and got a patent on the animal model. This drug exerts its therapeutic effect in chronic venous insufficiency, diabetic retinopathy, glaucoma and other micro-blood vessel disorders by reducing capillary permeability, improving lymphatic drainage, thus correcting leg and ankle oedema. Now the company has tied up with a Swiss company for clinical trials,” a company spokesperson said.
It has significant effects on endothelial integrity (endothelium is the inner lining of blood vessels) and increases endothelium-dependent relaxation owing to an increase in Nitric Oxide (NO) synthesis, the company said.
Ozone Pharmaceuticals, having manufacturing units at Baddi in Himachal Pradesh and Guwahati in Assam, is into prescribed drugs in the areas of antibiotics, antifungal, nutritional, anti-infective, and anxiolytics with special focus on cardiac and diabetic segments.
“The present invention relates to a pharmaceutical composition for treatment of diabetic and non-diabetic ocular neovascular complications cataract and glaucoma, said composition comprising: a) an active ingredient, selected from calcium benzene sulfonate salt compounds, in an amount such as herein described; and b) pharmaceutically acceptable excipients. Further, the present invention also relates to a pharmaceutical kit comprising the composition of the present invention, in a container, along with an instruction manual, optionally with an applicator,” according to the official note while granting the patent.